Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07231029

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

An Open-label Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Taisho Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment

Conditions

Interventions

TypeNameDescription
DRUGTS-172Single oral administration of TS-172 20mg

Timeline

Start date
2025-12-23
Primary completion
2026-10-26
Completion
2026-10-31
First posted
2025-11-17
Last updated
2026-01-09

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT07231029. Inclusion in this directory is not an endorsement.